Trials / Completed
CompletedNCT01049984
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 328 (actual)
- Sponsor
- Teva Neuroscience, Inc. · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasagiline | 1mg tablet daily for 18 weeks |
| DRUG | Placebo | one tablet daily for 18 weeks |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2010-01-15
- Last updated
- 2016-05-20
- Results posted
- 2014-10-15
Locations
58 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01049984. Inclusion in this directory is not an endorsement.